Holland & Barrett: A Decade of Financial Turbulence — From LetterOne to 2024 Restructuring

Holland & Barrett, the UK's largest health food and supplement retailer, has undergone a dramatic financial transformation over the past decade. From a high-profile leveraged buyout to a complex debt restructuring, the company's story reflects broader challenges facing brick-and-mortar health retail in an increasingly digital marketplace.

The LetterOne Acquisition and Early Optimism (2017–2019)

In 2017, Russian-linked investment firm LetterOne completed the acquisition of Holland & Barrett from Nature's Bounty Co. for approximately £1.77 billion. The deal was one of the largest in UK health retail history and signalled confidence in the growing wellness sector. At the time of purchase, the retailer operated over 1,300 stores across 16 countries, with revenues exceeding £600 million annually.

LetterOne's initial strategy focused on international expansion, digital transformation, and private-label product development. The company invested heavily in its e-commerce platform and launched a reformulated own-brand range targeting millennials and health-conscious consumers. Revenue grew modestly in 2018 and 2019, reaching an estimated £660 million.

COVID-19 and the Acceleration of Digital Shift (2020–2021)

The pandemic proved a double-edged sword for Holland & Barrett. While in-store footfall collapsed during lockdowns, online sales surged by over 80% in 2020. The company rapidly scaled its delivery infrastructure and launched click-and-collect services across its UK store network. Total revenues dipped to approximately £620 million in 2020 before recovering to £640 million in 2021.

However, the underlying financial structure remained heavily leveraged. The original acquisition debt of over £1 billion continued to weigh on the balance sheet, with annual interest payments consuming a significant portion of operating cash flow. EBITDA margins contracted from approximately 12% pre-pandemic to under 9% by the end of 2021.

Mounting Pressures and Strategic Pivots (2022–2023)

By 2022, Holland & Barrett faced a confluence of challenges: rising input costs driven by inflation, increased competition from online-only supplement brands like Myprotein and Bulk, and changing consumer preferences favouring personalised nutrition over traditional retail models. The company responded with a store rationalisation programme, closing approximately 100 underperforming locations while investing in flagship experiential stores.

Revenue stabilised around £630 million in 2022 but operating margins continued to erode. The company reported operating losses for the first time in its modern history, prompting a leadership restructure. A new CEO was appointed with a mandate to accelerate digital transformation and reduce the cost base by 15% within 18 months.

The 2024 Debt Restructuring

In early 2024, Holland & Barrett completed a significant debt restructuring that saw approximately £400 million of legacy acquisition debt converted to equity. The deal, negotiated with a consortium of creditors, effectively halved the company's debt burden and provided £50 million in new working capital. The restructuring was widely seen as essential to the company's survival as an independent entity.

Following the restructuring, the company announced a renewed five-year strategy focused on three pillars: digital-first retail, personalised health services (including in-store consultations and DNA-based supplement recommendations), and international expansion in Asia-Pacific markets. The company projected a return to profitability by 2026.

Outlook and Industry Implications

Holland & Barrett's decade of financial turbulence offers important lessons for the broader supplement industry. The company's experience highlights the risks of highly leveraged acquisitions in retail, the critical importance of digital transformation, and the challenges of competing in an increasingly fragmented wellness market.

As the global supplement market approaches $200 billion, Holland & Barrett's ability to execute its turnaround strategy will be closely watched by investors, competitors, and industry analysts alike. The company remains the UK's most recognised health retail brand, with strong consumer trust and an extensive store network — assets that, if properly leveraged, could support a successful transformation.

Many of the products discussed are manufactured in partnership with UK formulators including Supplement Factory.